STRATEC Biomedical AG (DE:SBS)
XETRA:SBS
Want to see DE:SBS full AI Analyst Report?
SBS Stock Chart & Stats
€22.40
€0.10(0.34%)
At close: 4:00 PM EST
€22.40
€0.10(0.34%)
Day’s Range― - ―
52-Week Range€16.34 - €33.10
Previous CloseN/A
Volume977.00
Average Volume (3M)15.55K
Market Cap
€206.65M
Enterprise Value€298.43M
Total Cash (Recent Filing)€23.74M
Total Debt (Recent Filing)€116.97M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 14, 2026EPS Estimate
0.24Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)-0.27
Shares Outstanding12,157,841
10 Day Avg. Volume11,323
30 Day Avg. Volume15,548
Financial Highlights & Ratios
PEG Ratio11.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.09
P/FCF Ratio-28.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€29.00Price Target Upside29.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.49
Revenue Forecast (FY)€269.29M
Bulls Say, Bears Say
Bulls Say
Systems / Instrument MomentumDouble-digit instrument growth reflects successful OEM platform adoption and creates a durable revenue base. As instruments scale, they underpin recurring service, consumables and spare-parts demand, improving long-term revenue visibility and leveraging fixed-cost investment across higher volumes.
Improved Cash GenerationSustained positive operating and free cash flow increases liquidity and funds operations, capex and R&D without immediate recourse to debt. Over months this supports execution of H2-weighted ramps and reduces refinancing risk while enabling disciplined investment per the company's plan.
Stronger Balance Sheet / Lower LeverageA solid equity base and reduced net leverage provide financial flexibility to absorb cyclical weakness and fund platform investments. Lower debt ratios improve resilience to earnings volatility and make multi-year OEM program investments and localized production easier to finance.
Bears Say
Multi-year Revenue DeclineA multi-year revenue downtrend reduces scale and weakens fixed-cost absorption for an OEM manufacturer. Persistent top-line decline risks lower operating leverage, constrains R&D and capital allocation, and makes hitting medium-term growth and margin targets harder without program wins or volume recoveries.
Margin Compression And Net LossesSharply compressed margins and a recent switch to net losses signal structural mix and scalability issues. Lower profitability reduces internally generated funds, weakens returns, hampers ability to hit 2028/2030 margin targets and increases sensitivity to input-cost or pricing pressures over the medium term.
High Inventory And Consumables Visibility RiskElevated inventories tie up capital and risk write‑downs from obsolescence, while weak consumables order visibility undermines recurring high-margin revenue. This combination increases working-capital volatility, threatens future margins and complicates reliable production planning over coming quarters.
STRATEC Biomedical News
SBS FAQ
What was STRATEC Biomedical AG’s price range in the past 12 months?
STRATEC Biomedical AG lowest stock price was €16.34 and its highest was €33.10 in the past 12 months.
What is STRATEC Biomedical AG’s market cap?
STRATEC Biomedical AG’s market cap is €206.65M.
When is STRATEC Biomedical AG’s upcoming earnings report date?
STRATEC Biomedical AG’s upcoming earnings report date is Aug 14, 2026 which is in 85 days.
How were STRATEC Biomedical AG’s earnings last quarter?
Currently, no data Available
Is STRATEC Biomedical AG overvalued?
According to Wall Street analysts STRATEC Biomedical AG’s price is currently Undervalued.
Does STRATEC Biomedical AG pay dividends?
STRATEC Biomedical AG pays a Annually dividend of €0.6 which represents an annual dividend yield of 2.71%. See more information on STRATEC Biomedical AG dividends here
What is STRATEC Biomedical AG’s EPS estimate?
STRATEC Biomedical AG’s EPS estimate is 0.24.
How many shares outstanding does STRATEC Biomedical AG have?
STRATEC Biomedical AG has 12,157,841 shares outstanding.
What happened to STRATEC Biomedical AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of STRATEC Biomedical AG?
Currently, no hedge funds are holding shares in DE:SBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
STRATEC Biomedical Stock Smart Score
Company Description
STRATEC Biomedical AG
Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers. The Diatron segment offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications. The Smart Consumables segment develops and manufactures smart consumables in the fields of diagnostics, life sciences, and medical technologies. The company was formerly known as STRATEC Biomedical AG and changed its name to Stratec SE in December 2018. Stratec SE was founded in 1979 and is headquartered in Birkenfeld, Germany.
SBS Stock 12 Month Forecast
Average Price Target
€29.00
▲(29.46% Upside)
Technical Analysis
Draegerwerk AG & Co. KGaA
―
Eckert & Ziegler Strahlen und Medizintechnik
―
First Sensor
―
Gerresheimer
―
Siemens Healthineers AG
―
Options Prices
Currently, No data available
---